On Friday, April 17, 2026, STAT+ reported that the U.S. Food and Drug Administration is evaluating expanded indications for testosterone therapy to treat hypoactive sexual desire disorder in women, a move that could reshape clinical approaches to female sexual health. The development comes amid growing interest in hormonal treatments for libido, particularly as researchers explore alternatives to dominant obesity drug pathways like GLP-1 receptor agonists.
The FDA’s review follows emerging clinical data suggesting that testosterone supplementation may improve sexual desire and satisfaction in postmenopausal women with low libido, a condition affecting an estimated 10% of women in this demographic. While testosterone is FDA-approved for male hypogonadism, its use in women remains off-label in the United States, though it is prescribed in some countries for sexual dysfunction. Regulators are now weighing whether sufficient evidence exists to support a formal indication for female sexual dysfunction, balancing potential benefits against risks such as acne, hair growth, and voice changes.
This regulatory scrutiny coincides with broader shifts in metabolic drug development. STAT+ highlighted that scientists behind foundational GLP-1 research are now questioning whether targeting the GLP-1 receptor is essential for effective weight loss treatments. Instead, they propose that dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors could yield comparable or superior weight reduction with fewer gastrointestinal side effects, such as nausea and vomiting, which commonly limit dosing and adherence in current GLP-1-based therapies.
One company at the forefront of this alternative approach is Kailera Therapeutics, which recently completed a $625 million initial public offering—the largest-ever Wall Street debut for a biopharmaceutical company, according to its investor relations disclosures. The proceeds are intended to advance Kailera’s obesity pipeline, including KAI-4729, a once-weekly injectable tri-agonist targeting GLP-1, GIP, and glucagon receptors, currently in Phase 1 trials in China. Another candidate, KAI-7535, is a once-daily oral GLP-1 receptor agonist under development to improve upon existing oral treatments’ tolerability and dosing convenience.
Kailera’s pipeline stems from a licensing agreement with Jiangsu Hengrui Pharmaceuticals, a major Chinese drugmaker, granting the U.S.-based company rights to develop and commercialize several metabolic therapies globally. The IPO proceeds will fund continued clinical testing, manufacturing scale-up, and potential regulatory submissions in the U.S. And Europe, should trial results support advancement.
The exploration of GIP-glucagon dual targeting builds on earlier research showing that glucagon receptor activation can increase energy expenditure and fat metabolism, while GIP modulation may enhance insulin sensitivity and reduce appetite. Preclinical studies cited in recent literature suggest that combining these mechanisms may produce additive weight loss effects without overstimulating the GLP-1 pathway, which is associated with delayed gastric emptying and related adverse events.
Experts caution, however, that while animal and early-phase human data are encouraging, larger and longer-term trials are needed to confirm both efficacy and safety profiles for GIP-glucagon-based therapies. Key concerns include potential impacts on heart rate, blood pressure, and hepatic fat accumulation, given glucagon’s role in glucose mobilization. Regulatory agencies will require robust cardiovascular outcome data before considering approval for chronic weight management indications.
In the testosterone space, the FDA has not announced a timeline for a decision on expanded labeling. Any potential approval would likely require post-marketing studies to monitor long-term safety, particularly regarding cardiovascular events and breast tissue effects, which have been debated in prior research on androgen therapy in women. Medical organizations such as the Endocrine Society and the International Society for the Study of Women’s Sexual Health have called for clearer guidelines on patient selection, dosing, and monitoring if testosterone becomes more widely available for female sexual dysfunction.
For patients and clinicians, the evolving landscape underscores the importance of individualized treatment approaches. While obesity and sexual health remain distinct therapeutic areas, both reflect a broader trend toward precision endocrinology—matching hormonal pathways to specific physiological goals with greater attention to tolerability and long-term outcomes. As research progresses, regulators, developers, and healthcare providers will continue to weigh innovation against evidence-based caution.
The next key checkpoint in this space will be the release of top-line results from Kailera’s Phase 1 trial of KAI-4729, expected later in 2026, which will provide initial insights into the safety and pharmacokinetics of its tri-agonist approach. Similarly, updates from the FDA regarding its review of testosterone for female sexual desire disorder are anticipated in the coming months, though no formal meeting dates have been publicly scheduled.
Readers interested in following these developments can monitor clinical trial registries such as ClinicalTrials.gov for updates on Kailera’s pipeline and FDA announcements via the agency’s official website for guidance on endocrine therapies. We welcome your thoughts and experiences in the comments below—please share this article if you found it informative.